Clonal dynamics on the road to hematological malignancy (MBL, MGUS, CH)

Monoclonal gammopathy of undetermined significance (MGUS), monoclonal B-cell lymphocytosis (MBL), and clonal hematopoiesis (CH) of indeterminate potential represent highly prevalent, age-associated precursor states characterized by detectable serological, cellular, or genetic alterations in otherwise asymptomatic individuals. The advent of high-sensitivity technologies, including mass spectrometry, multiparametric flow cytometry, and next-generation sequencing, has revealed that these conditions are far more widespread than previously appreciated, yet only a minority of affected individuals progress to overt malignancies such as multiple myeloma, chronic lymphocytic leukemia, or myeloid neoplasms. Across these entities, a unifying paradigm is emerging in which malignant transformation is governed not simply by the presence of driver lesions, but by dynamic clonal evolution shaped by intrinsic fitness, temporal acquisition of alterations, and selective pressures imposed by the aging microenvironment. In CH, mutation-specific growth kinetics and inflammation-driven selection define both hematologic and systemic risks. In MBL, antigenic stimulation, immune dysfunction, and genetic complexity modulate progression to CLL. In MGUS, disease evolution reflects a gradual co-evolution between plasma cell clones and a progressively permissive niche. Aging-associated inflammation and tissue remodeling act as common denominators, fostering a competitive landscape that selectively advantages aberrant clones while suppressing normal hematopoiesis. In turn, these clones actively remodel their microenvironment, establishing feed-forward loops that sustain clonal expansion and malignant potential. Integrating insights across CH, MBL, and MGUS highlights shared biological principles and supports a shift toward "precision prevention" strategies aimed at intercepting high-risk trajectories while minimizing unnecessary surveillance in low-risk individuals.